Clinical applications of azithromycin microspheres in respiratory tract infections

Francesco Blasi, Stefano Aliberti, Paolo Tarsia

Research output: Contribution to journalArticle

Abstract

Few adequately designed clinical trials have addressed optimal treatment duration in lower respiratory tract infections. Drugs possessing favourable pharmacokinetic and pharmacodynamic profiles may obtain early bacterial eradication allowing shorter treatment duration. This may be associated with a number of advantages including reduced resistance induction, increased compliance, lesser adverse events, and cost containment. Recently, a novel 2.0 g single dose of azithromycin microspheres has been compared with 7-day levofloxacin 500 mg or extended release clarithromycin in over 400 patients with community-acquired pneumonia. Clinical cure and bacteriological eradication rates, hospitalizations, and deaths were similar between azithromycin and comparators. Azitbromycin 2.0 g microspheres proved as effective as 7 days of levolloxacin 500 mg in acute exacerbation of chronic bronchitis patients across all degrees of obstruction severity. In both settings Azithromycin microspheres obtained clinical cure in most patients barbouring macrolide-resistant Streplococcus pneumoniae strains. The drug was well tolerated in clinical studies and in healthy volunteers with modest and transitory adverse events. An undoubted advantage of single-dose azithromycin administration is the facility in ensuring that patients complete their prescribed course of therapy. A further advantage of single-dose therapy is the potential for use as directly-observed therapy, which may be useful in specific clinical conditions.

Original languageEnglish
Pages (from-to)551-559
Number of pages9
JournalInternational Journal of Nanomedicine
Volume2
Issue number4
Publication statusPublished - 2007

Fingerprint

Azithromycin
Microspheres
Respiratory Tract Infections
Pharmacodynamics
Pneumonia
Pharmacokinetics
Directly Observed Therapy
Levofloxacin
Clarithromycin
Cost Control
Chronic Bronchitis
Macrolides
Therapeutics
Pharmaceutical Preparations
Compliance
Healthy Volunteers
Hospitalization
Clinical Trials
Mortality
Costs

Keywords

  • Azithromycin mierospheres
  • COPD exacerbations
  • Pneumonia

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Organic Chemistry
  • Drug Discovery

Cite this

Clinical applications of azithromycin microspheres in respiratory tract infections. / Blasi, Francesco; Aliberti, Stefano; Tarsia, Paolo.

In: International Journal of Nanomedicine, Vol. 2, No. 4, 2007, p. 551-559.

Research output: Contribution to journalArticle

@article{0ef1d94aed704e57bf1d8fdd1a49031e,
title = "Clinical applications of azithromycin microspheres in respiratory tract infections",
abstract = "Few adequately designed clinical trials have addressed optimal treatment duration in lower respiratory tract infections. Drugs possessing favourable pharmacokinetic and pharmacodynamic profiles may obtain early bacterial eradication allowing shorter treatment duration. This may be associated with a number of advantages including reduced resistance induction, increased compliance, lesser adverse events, and cost containment. Recently, a novel 2.0 g single dose of azithromycin microspheres has been compared with 7-day levofloxacin 500 mg or extended release clarithromycin in over 400 patients with community-acquired pneumonia. Clinical cure and bacteriological eradication rates, hospitalizations, and deaths were similar between azithromycin and comparators. Azitbromycin 2.0 g microspheres proved as effective as 7 days of levolloxacin 500 mg in acute exacerbation of chronic bronchitis patients across all degrees of obstruction severity. In both settings Azithromycin microspheres obtained clinical cure in most patients barbouring macrolide-resistant Streplococcus pneumoniae strains. The drug was well tolerated in clinical studies and in healthy volunteers with modest and transitory adverse events. An undoubted advantage of single-dose azithromycin administration is the facility in ensuring that patients complete their prescribed course of therapy. A further advantage of single-dose therapy is the potential for use as directly-observed therapy, which may be useful in specific clinical conditions.",
keywords = "Azithromycin mierospheres, COPD exacerbations, Pneumonia",
author = "Francesco Blasi and Stefano Aliberti and Paolo Tarsia",
year = "2007",
language = "English",
volume = "2",
pages = "551--559",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",
number = "4",

}

TY - JOUR

T1 - Clinical applications of azithromycin microspheres in respiratory tract infections

AU - Blasi, Francesco

AU - Aliberti, Stefano

AU - Tarsia, Paolo

PY - 2007

Y1 - 2007

N2 - Few adequately designed clinical trials have addressed optimal treatment duration in lower respiratory tract infections. Drugs possessing favourable pharmacokinetic and pharmacodynamic profiles may obtain early bacterial eradication allowing shorter treatment duration. This may be associated with a number of advantages including reduced resistance induction, increased compliance, lesser adverse events, and cost containment. Recently, a novel 2.0 g single dose of azithromycin microspheres has been compared with 7-day levofloxacin 500 mg or extended release clarithromycin in over 400 patients with community-acquired pneumonia. Clinical cure and bacteriological eradication rates, hospitalizations, and deaths were similar between azithromycin and comparators. Azitbromycin 2.0 g microspheres proved as effective as 7 days of levolloxacin 500 mg in acute exacerbation of chronic bronchitis patients across all degrees of obstruction severity. In both settings Azithromycin microspheres obtained clinical cure in most patients barbouring macrolide-resistant Streplococcus pneumoniae strains. The drug was well tolerated in clinical studies and in healthy volunteers with modest and transitory adverse events. An undoubted advantage of single-dose azithromycin administration is the facility in ensuring that patients complete their prescribed course of therapy. A further advantage of single-dose therapy is the potential for use as directly-observed therapy, which may be useful in specific clinical conditions.

AB - Few adequately designed clinical trials have addressed optimal treatment duration in lower respiratory tract infections. Drugs possessing favourable pharmacokinetic and pharmacodynamic profiles may obtain early bacterial eradication allowing shorter treatment duration. This may be associated with a number of advantages including reduced resistance induction, increased compliance, lesser adverse events, and cost containment. Recently, a novel 2.0 g single dose of azithromycin microspheres has been compared with 7-day levofloxacin 500 mg or extended release clarithromycin in over 400 patients with community-acquired pneumonia. Clinical cure and bacteriological eradication rates, hospitalizations, and deaths were similar between azithromycin and comparators. Azitbromycin 2.0 g microspheres proved as effective as 7 days of levolloxacin 500 mg in acute exacerbation of chronic bronchitis patients across all degrees of obstruction severity. In both settings Azithromycin microspheres obtained clinical cure in most patients barbouring macrolide-resistant Streplococcus pneumoniae strains. The drug was well tolerated in clinical studies and in healthy volunteers with modest and transitory adverse events. An undoubted advantage of single-dose azithromycin administration is the facility in ensuring that patients complete their prescribed course of therapy. A further advantage of single-dose therapy is the potential for use as directly-observed therapy, which may be useful in specific clinical conditions.

KW - Azithromycin mierospheres

KW - COPD exacerbations

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=56049127657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049127657&partnerID=8YFLogxK

M3 - Article

C2 - 18203423

AN - SCOPUS:56049127657

VL - 2

SP - 551

EP - 559

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

IS - 4

ER -